Results 201 to 210 of about 328,812 (261)

Histone acetylases are required for iron homeostasis in yeast

Acta Biochimica et Biophysica Sinica
Zhang Jian, Xue Yong, Zhang Xinya, Qi Renjie, Zhang Yaqi, Lu Chen, Luo Zhidan   +6 more
doaj   +1 more source

Engineered extracellular vesicles enriched with the miR‐214/199a cluster enhance the efficacy of chemotherapy in ovarian cancer

Molecular Oncology, EarlyView.
Loss of the miR‐214/199a cluster is associated with recurrence in ovarian cancer. Engineered small extracellular vesicles (m214‐sEVs) elevate miR‐214‐3p/miR‐199a‐5p in tumor cells, suppress β‐catenin, TLR4, and YKT6 signaling, reprogram tumor‐derived sEV cargo, reduce chemoresistance and migration, and enhance carboplatin efficacy and survival in ...
Weida Wang, Ayesha Alvero, Yi Qin, Mingjin Wang, Alexandra Fox, Yanfeng Li, Michael Millman, Amy Kemper, Gil Mor, Xian Shuang Liu, Michael Chopp, Zheng Gang Zhang, Yi Zhang   +12 more
wiley   +1 more source

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source

Keratin 19 as a prognostic marker and contributing factor of metastasis and chemoresistance in high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Keratin 19 (KRT19) is overexpressed in high‐grade serous ovarian cancer with high levels of Kallikrein‐related peptidases (KLK) 4–7 and is associated with poor survival. In vivo analyses demonstrate that elevated KRT19 increases peritoneal tumour burden.
Sophia Bielesch, Isabel Vogel, Sina Nokodian, Johanna Moeller, Antonia Blechschmidt, Vicky Hecht, Vanessa Kuentzel, Katharina Thiedig, Melissa Schwab, Oliver Schilling, Holger Bronger, Marion Kiechle, Viktor Magdolen, Tobias Dreyer   +13 more
wiley   +1 more source

Compound screening in primary human airway basal cells identifies Wnt pathway activators as potential pro-regenerative therapies

Ishii Y, Orr JC, El Mdawar M, de Pilger DRB, Pearce DR, Lazarus KA, Graham RE, Nikolić MZ, Ketteler R, Carragher NO, Janes SM, Hynds RE.   +11 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Schistosomes: challenges in compound screening

Expert Opinion on Drug Discovery, 2007
Major progress in studying the biology of schistosomes had been achieved since the late 1960s with the successful laboratory cultivation of the parasite's life cycle stages in the vertebrate (in vivo animal models) and snail hosts. This was followed by establishment of in vitro culture techniques for cultivation of the different life cycle stages to ...
Quentin Bickle, Solomon Nwaka, Fouad Yousif   +2 more
exaly   +3 more sources

Ultraviolet radiation screening compounds

Biological Reviews, 1999
ABSTRACTAmongst the diversity of methods used by organisms to reduce damage caused by ultraviolet (UV) radiation, the synthesis of UV‐screening compounds is almost ubiquitous. UV‐screening compounds provide a passive method for the reduction of UV‐induced damage and they are widely distributed across the microbial, plant and animal kingdoms. They share
C S, Cockell, J, Knowland
openaire   +2 more sources

The Future of Virtual Compound Screening

Chemical Biology & Drug Design, 2012
We provide a future perspective of the virtual screening field. A number of challenges will be highlighted that virtual screening will likely face when compound data will further grow at or beyond current rates and when much more target information will become available.
Kathrin, Heikamp, Jürgen, Bajorath
openaire   +2 more sources

The evolution of microarrayed compound screening

Drug Discovery Today, 2004
This review describes recent developments in the evolutionary process of microarrayed compound screening (microARCS to become a robust and efficient ultra-high-throughput screening technology. Improvements in compound spotting (including new quality-control methods), gel casting and imaging, together with software capable of automatic analysis and ...
Michael, Hoever, Peter, Zbinden
openaire   +2 more sources

A network view of disease and compound screening

Nature Reviews Drug Discovery, 2009
The large-scale generation and integration of genomic, proteomic, signalling and metabolomic data are increasingly allowing the construction of complex networks that provide a new framework for understanding the molecular basis of physiological or pathophysiological states.
Eric E, Schadt, Stephen H, Friend, David A, Shaywitz   +2 more
openaire   +2 more sources